Introduction {#Sec1}
============

Previous research has demonstrated a correlation between dosing burden and medication nonadherence \[[@CR1]--[@CR3]\]. In type 2 diabetes mellitus (T2DM), therapies including combinations of oral antihyperglycemic drugs (OADs) can result in high nonadherence \[[@CR4]\]. However, poor adherence to oral antidiabetes therapies is not limited to combination therapies and is common among patients just starting monotherapy \[[@CR5]\]. A number of studies have demonstrated that patients with T2DM are willing to forgo the benefits of treatment to reduce treatment burden \[[@CR6]\] and have identified a relationship between patients' preferences and likely medication adherence \[[@CR7], [@CR8]\]. Other studies have suggested that less frequent dosing may result in greater patient adherence, improved treatment outcomes, and reduced health care costs \[[@CR9]--[@CR12]\].

Discrete-choice experiments (DCEs), also known as choice-format conjoint analysis studies, increasingly have been used to determine the tradeoffs that patients are willing to make among features of medical interventions \[[@CR13]--[@CR15]\]. This method is based on the premise that medical interventions are composed of a set of attributes or outcomes, that the attractiveness of a particular intervention to an individual is a function of these attributes, and that choices among alternatives reveal patients' relative preferences for these attributes \[[@CR16]\]. A recent study demonstrated that patients with T2DM have preferences for reducing the dosing burden of combination OAD therapy and that patients with lower current overall medication burden were more likely to indicate that decreases in dosing burden would result in an improvement in their expected medication adherence \[[@CR7]\]. The objective of the current study was to elicit preferences for alternative dosing regimens for OAD therapies among patients with T2DM and to quantify differences in dosing preferences among patients with different characteristics.

Methods {#Sec2}
=======

Study Sample {#Sec3}
------------

Patients were recruited from a probability-based, nationally representative panel of United States (US) households maintained by Knowledge Networks (Palo Alto, CA, USA). To qualify for inclusion in this study, patients had to (1) be aged 18 years or older; (2) have a self-reported physician diagnosis of T2DM; (3) be currently taking one OAD or no OAD to treat their T2DM; and (4) be not currently taking injectable T2DM treatments (e.g., insulin and glucagon-like-1 receptor agonist). Email invitations were sent to potential panelists based on self-reported physician diagnosis of T2DM. The sample was stratified by age (18--44, 45--64, ≥65 years), time since diagnosis (≤3, \>3 years), and treatment status (no current OAD, one current OAD).

Survey Instrument {#Sec4}
-----------------

The online DCE survey was adapted from a survey used in a previous study \[[@CR7]\] and developed using good research practices \[[@CR13]\]. The survey included a series of eight choice questions; each question presented a pair of hypothetical, but realistic, OAD medication profiles (Fig. [1](#Fig1){ref-type="fig"}). Patients were asked to choose their preferred medication profile in each pair. Each profile was defined by five clinical outcomes, dosing schedule, and out-of-pocket cost. Clinical outcomes included reduction in average glucose (AG) \[[@CR17]\] (between 20 and 66 mg/dL) from a baseline of 206 mg/dL, chance of mild-to-moderate gastrointestinal side effects (between 10% and 30%), frequency of hypoglycemia (between none and \>2 hypoglycemic episodes per month), weight change within the first 6 months after starting treatment (between 6 lb weight gain and 6 lb weight loss), and incremental treatment-related risk of congestive heart failure (CHF) (between 0% and 3%). The combination of attributes in each medication profile and the pairing of profiles in each choice question were determined by an experimental design with known statistical properties developed using good research practices \[[@CR18]\].Fig. 1Example of a choice question in the discrete-choice experiment. *CHF* congestive heart failure

Relevant clinical attributes and dosing options were identified based on a review of clinical literature, product labels, and ongoing clinical trials in the public domain for OADs, and in consultation with clinical experts \[[@CR7]\]. The ranges of the attribute levels were chosen to encompass the range of outcome levels described in the clinical trials literature, as well as the range over which patients were willing to accept tradeoffs \[[@CR7]\]. The dosing attribute included three levels (one pill once daily, two pills once daily, and one pill twice daily) based on available starting doses for common OADs prescribed to patients just starting monotherapy. The dosing attribute also included a once-weekly level to account for the future possibility of a once-weekly dipeptidyl peptidase-4 (DDP-4) inhibitor (ClinicalTrials.gov Identifier NCT01814748). Levels of out-of-pocket cost ranged from \$0 per month to \$200 per month and spanned the range over which the majority of patients were willing to trade among cost and other attributes in pretest interviews. The validity of the survey instrument was evaluated during 14 face-to-face qualitative pretest interviews with a convenience sample of patients with T2DM.

Following the choice questions, each patient was presented with a direct question about dosing preference (Fig. [2](#Fig2){ref-type="fig"}). Specifically, each patient was asked to indicate his or her preferred dosing schedule from four possible dosing schedules, assuming all other treatment characteristics were constant across alternatives.Fig. 2Direct dosing question

The survey also collected data on demographic characteristics, health history, and treatment experience. The study and survey design were approved by Research Triangle Institute's Office of Research Protection and Ethics. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 and 2008. All patients were required to provide informed consent before completing the survey. A copy of the survey instrument is available from the corresponding author upon request.

Statistical Analysis {#Sec5}
--------------------

The medication choice data were analyzed using a random-parameters logit model with NLOGIT 4.0 (Econometric Software, Inc, Plainview, NY, USA). Random-parameters logit controls for unobserved preference heterogeneity among respondents by estimating a distribution for each preference parameter \[[@CR19], [@CR20]\]. The resulting parameter estimates can be interpreted as relative preference weights. The difference between the relative preference weights on the best and worst levels of the attribute is the relative importance of each attribute over the range of levels included in the survey.

The proportion of patients who preferred once-weekly dosing over daily-dosing alternatives was calculated for the overall sample and for each of the prespecified subgroups. For each pair of subgroups, *P* values (*α* = 0.05) were calculated using a Chi-squared test of the difference between the proportion of patients who preferred once-weekly dosing and the proportion of patients who preferred once-daily dosing.

Results {#Sec6}
=======

Study Sample {#Sec7}
------------

A total of 2,262 email invitations were sent to panel members. Of the 940 patients who responded and consented to participate, 13 patients were excluded from the analysis because they had no variation in their responses (i.e., they chose either Medicine A or Medicine B for every choice question). This response pattern indicated that the patient was inattentive to the choice questions. An additional 4 patients did not complete any of the choice questions. The final sample included 923 respondents with a mean age of 63 years; 45% of the respondents were male, and 79% were white. Most respondents (79%) reported that they were currently using an OAD. Table [1](#Tab1){ref-type="table"} summarizes the characteristics of the respondents.Table 1Patient characteristicsCharacteristicsPatients (*N* = 923)Male45%White79%Have health insurance^a^95%Currently being treated with OADs79%Mean age, years (SD)63 (11)Age subgroups 18--44 years6.7% 45--64 years47.6% ≥65 years45.7%Treatment status On treatment (currently taking an OAD)726 Not on treatment (not currently taking an OAD)197Time since diagnosis^b^ ≤3 years271 \>3 years645*OADs* oral antihyperglycemic drugs, *T2DM* type 2 diabetes mellitus, *SD* standard deviation^a^Six respondents with missing data^b^Seven respondents did not report when they were first diagnosed with T2DM

Relative Importance Scores {#Sec8}
--------------------------

Relative importance scores are presented in Fig. [3](#Fig3){ref-type="fig"}. The distance between preference weights for the best level and worst level of an attribute can be interpreted as the overall relative importance of the attribute over the range of levels assessed in the survey. Over the ranges of levels included in the study, out-of-pocket cost (between \$0 and \$200 per month) was the most important treatment attribute and was statistically significantly more important than efficacy, side effects, and dosing. Reduction in AG was statistically significantly more important than dosing and the remaining clinical outcomes. Hypoglycemia, chance of mild-to-moderate gastrointestinal side effects, weight change within the first 6 months of starting treatment, and incremental increase in the risk of CHF were of approximately equal importance. Once-weekly dosing was preferred to one pill once daily. One pill once daily was preferred to one pill twice daily, which, in turn, was preferred to two pills once daily. The difference in preference weights between the most preferred dosing option (one pill once weekly) and one pill once daily was positive and statistically significant; however, changes in dosing schedule were relatively less important than medication cost or changes in clinical outcomes over the ranges of attribute levels included in this study.Fig. 3Relative importance scores for attributes in the discrete-choice experiment. The largest relative importance score was set equal to 10 and all other relative importance scores were calculated relative to the largest relative importance score

Dosing Preferences {#Sec9}
------------------

Patients' dosing preferences are presented in Fig. [4](#Fig4){ref-type="fig"}. Among all patients, 67% preferred weekly dosing to any of the daily-dosing schedules. Among patients not currently taking any OAD, 75% preferred once-weekly dosing to daily-dosing options. This proportion was statistically significantly greater (*P* = 0.012) than the 65% of patients currently using an OAD who preferred once-weekly dosing over daily dosing. Among younger patients (aged \<45 years), 78% preferred once-weekly dosing to daily dosing; in contrast, 66% of patients aged 45--64 years (*P* = 0.065 vs. the younger age group) and 66% of patients aged 65 years or older (*P* = 0.074 vs. the younger age group) preferred once-weekly dosing to daily dosing, although these findings were not statistically significant. Similar proportions of patients whose T2DM was diagnosed within the previous 3 years and patients whose T2DM was diagnosed more than 3 years ago preferred once-weekly dosing to daily dosing: 66% of patients with a more recent diagnosis preferred once-weekly dosing, and 67% of patients with a diagnosis more than 3 years ago preferred once-weekly dosing.Fig. 4Proportion of patients preferring weekly dosing to daily dosing. All proportions are statically significantly different within the overall sample, within the subgroups, and across the subgroup pairings, except the following comparisons: respondents aged 18--44 years and respondents aged 45--64 years (*P* = 0.065); respondents aged 18--44 years and respondents aged ≥65 years (*P* = 0.074); and respondents whose T2DM was diagnosed ≤3 years ago and respondents whose T2DM was diagnosed \>3 years ago (*P* = 0.864). *T2DM* type 2 diabetes mellitus

Discussion {#Sec10}
==========

Dosing burden has been found to influence patients' expectations about medication adherence in T2DM \[[@CR7]\] and in other chronic diseases \[[@CR21]\]. In this study, we administered a survey among patients with T2DM to elicit their preferences among treatment attributes (including efficacy, tolerability, daily dosing, and cost) to quantify the relative importance of reducing OAD dosing burden. Dosing preferences were elicited using both a DCE and a direct question.

Many studies have examined patients' preferences for dosing; however, the results of these studies are mixed. Some studies find that patients have statistically significant preferences for less frequent dosing while others do not. For example, Hauber et al. \[[@CR7]\] found that patients with T2DM had statistically significant preferences for reducing daily-dosing frequency, especially among patients with lower current dosing burdens. Likewise, de Bekker-Grob et al. \[[@CR22]\] found that reducing the frequency of dosing for osteoporosis prophylaxis was approximately equally important as reducing the 10-year risk of osteoporosis by 10 percentage points among women in the Netherlands. In contrast, Lancsar et al. \[[@CR23]\] and King et al. \[[@CR24]\] found that preferences for reducing the frequency of daily dosing of asthma medications were not statistically significant predictors of treatment choice among asthma patients in Australia.

Although dosing was less important to patients with T2DM than clinical outcomes and cost in this study, patients had strong and statistically significant preferences for changes in dosing. In addition, patients had strong and statistically significant preferences for once-weekly dosing relative to alternative daily-dosing regimens. Patients not currently taking an OAD had stronger preferences for weekly dosing than did patients who were currently taking an OAD. A higher proportion of patients aged 44 years and younger preferred once-weekly dosing to once-daily dosing when compared with patients aged 45 years and older, although this difference was not statistically significant. The lack of statistical significance for the difference in preferences for once-weekly dosing (12 percentage points) between younger and older patients may be due to the small sample size in the lower age group. Time since diagnosis did not have a measureable impact on dosing preferences among the patients in this study.

As all stated-preference studies, this study is subject to limitations. The results of this study should be interpreted with these limitations in mind. First, the survey asked patients to evaluate hypothetical scenarios. Although this practice is commonly used for eliciting patient preferences, the choices indicated by patients do not have the same impact as actual choices. In addition, none of the patients in this study had prior experience with weekly or less frequent dosing of OADs. Therefore, we cannot make any definitive statements about the effect of this type of experience on dosing preferences. Second, our study implicitly assumes that all clinical, convenience, and economic attributes of treatment that are not included in the DCE are held constant across the alternatives presented in the choice questions. In theory, adding these attributes to the DCE should not change our results; however, it is unknown whether including additional attributes in or deleting attributes from this particular study would yield different results. Finally, diagnosis of T2DM was self-reported, and the final sample may not be representative of the population of patients with T2DM in the US.

Patients in this study were asked to indicate which of four possible OAD dosing options they preferred. Overall, and in each subgroup evaluated in this study, patients preferred once-weekly dosing to daily dosing. These preferences were stronger for younger patients and patients not currently taking an OAD.

Conclusion {#Sec11}
==========

All attributes used to describe T2DM medications were important to patients. Cost and glucose control had the greatest impact on treatment choice, indicating that although achieving treatment objectives is important to patients with T2DM, these patients may be willing to forgo optimal glucose control to avoid out-of-pocket costs. Dosing, tolerability, and adverse event risks were relatively less important than cost and glucose control; however, these treatment attributes were not unimportant in treatment choice. The majority of patients preferred once-weekly dosing to more frequent dosing. Patients not currently on treatment and younger patients (aged \<45 years) were more likely to prefer once-weekly dosing to daily dosing. Therefore, for younger patients and patients not currently on treatment, once-weekly dosing may provide additional incentive to initiate and adhere to antihyperglycemic treatment. However, additional research will be required to confirm this hypothesis.
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